AstraZeneca's Crestor no better than Lipitor in reducing plaque in arteries
This article was originally published in Scrip
AstraZeneca has failed to show that its cholesterol lowering drug, Crestor (rosuvastatin), is better than atorvastatin (Pfizer's Lipitor), in reducing plaque in the arteries of the heart following two years of treatment. The AstraZeneca drug did demonstrate some statistically significant differences from the performance of Lipitor in a number of lipid parameters. This publication of the results comes as Lipitor goes off patent, an event that some analysts believe will serve to erode Crestor sales.
You may also be interested in...
Danish firm Topotarget said it was 'very confident' that it will be able to raise its first milestone from partner, Spectrum Pharmaceuticals, by the third quarter as it reported that final top-line data confirm that the primary endpoint was met in the Phase II BELIEF trial investigating an intravenous formulation of the histone deacetylase (HDAC) inhibitor, belinostat, for peripheral T-cell lymphoma (PTCL).
AstraZeneca's Caprelsa (vandetanib) has become the first treatment to be approved for advanced medullary thyroid cancer (MTC) in Europe after being granted marketing authorisation by the European Commission.
Despite reporting positive weight loss data from the third of four Phase IIIa trials from the SCALE program investigating liraglutide (Victoza) for obesity Novo Nordisk has failed to dazzle analysts who have questioned the commercial potential of the drug in this arena.